Business Context and Reporting Period
This Form 6-K filing by Kamada Ltd. (Nasdaq: KMDA) covers the period ending August 16, 2018. Kamada is a plasma-derived protein therapeutics company focused on orphan indications, with its flagship product GLASSIA® (Alpha-1 Antitrypsin) and a portfolio of other immune globulins. The filing primarily addresses the resolution of a labor strike at the company's Beit Kama production facility in Israel.
Key Financial Metrics
- One-Time Loss: The company will report a one-time loss of $1 million in the third quarter of 2018 due to the loss of in-process material caused by the work stoppage.
- Revenue and Profit: The filing does not provide specific revenue, profit, or cash flow figures for the period. The company is currently assessing the full-year 2018 revenue impact of the strike.
- Liquidity and Debt: No specific data regarding debt levels or liquidity positions is provided in this document.
Material Changes
- Strike Resolution: A binding Memorandum of Understanding (MoU) was signed on August 15, 2018, terminating the labor strike. All unionized employees have returned to work.
- Operational Impact: The strike had no impact on the market availability of GLASSIA® or KEDRAB®.
- Future Agreements: The MoU serves as the basis for a new four-year collective bargaining agreement to be finalized within 60 days.
Guidance, Outlook, and Risks
- Guidance Update: Kamada will provide an update on its previously issued full-year 2018 revenue guidance in the near term following an assessment of the strike's impact.
- Risks and Contingencies: The filing highlights risks associated with labor disputes and the uncertainty of finalizing the new collective bargaining agreement. Forward-looking statements regarding revenue guidance and strike effects are subject to material risks and uncertainties.
- Unusual Items: The $1 million loss in Q3 is classified as a one-time item resulting from the strike.
Investor Verification Checklist
- Verify the updated full-year 2018 revenue guidance once released by management.
- Confirm the final terms of the new four-year collective bargaining agreement.
- Monitor the Q3 2018 financial report for the precise accounting of the $1 million one-time loss.
- Review the Form 20-F for detailed risk factors regarding labor relations and production continuity.